New multi-cancer early detection test developed by GRAIL ranked as one of the most important potential employee benefits

New York, NY and Menlo Park, CA, February 6, 2023 — A recent Ipsos poll* conducted on behalf of GRAIL finds that a majority of eligible employees would want to know as early as possible if they had cancer, and would use a product that matches the description of the Galleri® test (hereafter, Galleri®) if it were offered as a no-cost benefit by their employer (see methodology below for details). “Eligible employees” (hereafter, employees) are those employed full-time at medium to large companies, and are considered eligible to receive the Galleri® test due to being aged 50 or older, or having other elevated risks of cancer. Furthermore, when asked about potential benefits that an employer might offer, employees ranked Galleri® as the most important, on par with an incremental $1000 salary increase. The survey results also suggest that Galleri® could positively impact employees’ perceptions of their employer and could lead to higher employee satisfaction. In addition, employees believe that using Galleri® could have a positive emotional impact, including giving them a sense of control over their health.

Detailed findings:

1. Vast majority (92%) of employees surveyed agree that they would want to know as early as possible if they had cancer.

2. After exposure to a blinded Galleri® test profile (see methodology for details), the majority (84%) of employees say they would use the test in the next six months if it were offered as a benefit from their employer at no cost to them.

3. 95% of employees surveyed feel that Galleri®, if offered as an employee benefit, would meet the needs of employees like them very well or fairly well.

4. Galleri® is ranked as one of the most important potential benefits (among the 14 tested), on par with an incremental $1000 salary increase and ahead of other traditional benefits. This is shown by relative importance score, on a scale of 0 to 100, with 0 meaning not at all important and 100 meaning highest importance relative to the other items

• Importance score of 79.1 for Galleri®
• Importance score of 77.7 for a $1,000 salary increase
• Importance score of 68.9 for an incremental 1% 401k match increase
• Importance score of 61.6 for flexible work arrangements
• Importance score of 59.2 for cardiovascular health programs
• Importance score of 43.5 for genetic risk factor testing
• Importance score of 39.9 for on-demand medicine
• Importance score of 30.6 for weight management program
• Importance score of 21.1 for sleep health program
• Importance score of 19.7 for digital mental health solution

5. Offering the Galleri® test as a benefit could positively impact employees’ perceptions of their employer. Perceptual changes include most employees agreeing that a company offering the test:

• Shows a commitment to fighting cancer (84%)
• Is helping to minimize employees’ healthcare costs (83%)
• Is innovative (82%)
• Cares about the health and wellbeing of its employees (81%)
• Values and invests in its employees (79%)
• Cares about providing access to healthcare benefits for a diverse employee population (77%)
• Prioritizes the mental health of its employees (57%)

6. In addition, offering Galleri® as a benefit has potential to increase employee satisfaction, retention and attraction:

• Three-quarters (76%) of employees agree that they would be more satisfied with their employer if they offered the Galleri® test as a no-cost benefit
• Half (51%) agree that if their employer offered Galleri®, they would be more likely to stay at the company
• Two-thirds (69%) of employees say that if a potential new employer offered Galleri® as a benefit at no cost to them, it would have at least some impact on their consideration of that company versus other prospective employers

7. Most employees believe using Galleri® could have a positive emotional impact:

• 87% agree that using Galleri® would make them feel like they had taken proactive action in terms of their health
• 79% agree that using Galleri® would give them a sense of control
• 75% agree that using Galleri® would make them feel empowered

About the Study - Ipsos Health Systems Market Research for GRAIL

Conducted by Ipsos using M360 Research’s https://www.m360research.com/ and https://www.m3globalresearch.com/ proprietary panels and two other partner panels (Dynata  https://www.dynata.com/ and Luc.ID (a Cint group company;  https://www.cint.com/).

A survey of employees at elevated risk for cancer (ages 50+ or age 35-49 at high risk^) working at medium to large US companies (of 3,000+ employees)

Interview dates: August 18 – September 8, 2022

Number of interviews: 1000

Number of participants aged 50 or older: 850

Number of participants aged 35-49 and considered high-risk^: 150

^ defined as individuals who have:

• At least one of these risk factors: cirrhosis or chronic Hepatitis B or C infection, infection with certain strains of HPV (e.g., 16 or 18), known hereditary cancer syndrome, had cancer at least 3 years ago, and/or are current smokers or quit smoking less than 10 years ago.
• At least two of these risk factors: documented genetic predisposition to cancer, first degree relative with cancer, HIV, use immunosuppressive therapies after organ transplantation, diabetes, and/or high BMI (i.e., ≥30 for females and ≥35 for males)

All participants were screened to ensure they are full-time employees working at medium to large companies (of 3000+ employees)

Credibility Interval: +/- 3.8 percentage points at the 95% confidence level

In our reporting of the findings, percentage points are rounded off to the nearest whole number. As a result, percentages in a given table column may total slightly higher or lower than 100%. In questions that permit multiple responses, columns may total substantially more than 100%, depending on the number of different responses offered by each respondent.

NOTE: All results show percentages among all respondents, unless otherwise labeled.

About Ipsos

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

Our tagline "Game Changers" sums up our ambition to help our 5,000 customers move confidently through a rapidly changing world.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP